Cargando…
Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report
Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomati...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084234/ https://www.ncbi.nlm.nih.gov/pubmed/35615334 http://dx.doi.org/10.4084/MJHID.2022.043 |
_version_ | 1784703567258451968 |
---|---|
author | Di Palma, Martina Gentilini, Elio Masucci, Chiara Micozzi, Alessandra Turriziani, Ombretta Mulè, Antonino Foà, Robin Martelli, Maurizio D’Ettorre, Gabriella Capria, Saveria Chiaretti, Sabina |
author_facet | Di Palma, Martina Gentilini, Elio Masucci, Chiara Micozzi, Alessandra Turriziani, Ombretta Mulè, Antonino Foà, Robin Martelli, Maurizio D’Ettorre, Gabriella Capria, Saveria Chiaretti, Sabina |
author_sort | Di Palma, Martina |
collection | PubMed |
description | Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomatic for COVID-19, the first dose of inotuzumab was administered, followed by remdesivir as prophylaxis. However, a worsening in respiratory findings led to a delay in administering the following doses of inotuzumab. Interestingly, even if the patient did not receive the full inotuzumab cycle, he achieved a complete hematologic remission: furthermore, he spontaneously developed anti-sars-COV2 antibodies. COVID-19 treatment also included convalescent plasma, leading to negativization of the viral load. The patient, after COVID-19 recovery, received a second full cycle of inotuzumab, underwent allogeneic transplantation, and is currently in complete hematologic and molecular remission, in good clinical conditions, five months from allograft. |
format | Online Article Text |
id | pubmed-9084234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Università Cattolica del Sacro Cuore |
record_format | MEDLINE/PubMed |
spelling | pubmed-90842342022-05-24 Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report Di Palma, Martina Gentilini, Elio Masucci, Chiara Micozzi, Alessandra Turriziani, Ombretta Mulè, Antonino Foà, Robin Martelli, Maurizio D’Ettorre, Gabriella Capria, Saveria Chiaretti, Sabina Mediterr J Hematol Infect Dis Case Report Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomatic for COVID-19, the first dose of inotuzumab was administered, followed by remdesivir as prophylaxis. However, a worsening in respiratory findings led to a delay in administering the following doses of inotuzumab. Interestingly, even if the patient did not receive the full inotuzumab cycle, he achieved a complete hematologic remission: furthermore, he spontaneously developed anti-sars-COV2 antibodies. COVID-19 treatment also included convalescent plasma, leading to negativization of the viral load. The patient, after COVID-19 recovery, received a second full cycle of inotuzumab, underwent allogeneic transplantation, and is currently in complete hematologic and molecular remission, in good clinical conditions, five months from allograft. Università Cattolica del Sacro Cuore 2022-05-01 /pmc/articles/PMC9084234/ /pubmed/35615334 http://dx.doi.org/10.4084/MJHID.2022.043 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Di Palma, Martina Gentilini, Elio Masucci, Chiara Micozzi, Alessandra Turriziani, Ombretta Mulè, Antonino Foà, Robin Martelli, Maurizio D’Ettorre, Gabriella Capria, Saveria Chiaretti, Sabina Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report |
title | Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report |
title_full | Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report |
title_fullStr | Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report |
title_full_unstemmed | Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report |
title_short | Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report |
title_sort | management of relapsed/refractory all with inotuzumab during covid-19. a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084234/ https://www.ncbi.nlm.nih.gov/pubmed/35615334 http://dx.doi.org/10.4084/MJHID.2022.043 |
work_keys_str_mv | AT dipalmamartina managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport AT gentilinielio managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport AT masuccichiara managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport AT micozzialessandra managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport AT turrizianiombretta managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport AT muleantonino managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport AT foarobin managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport AT martellimaurizio managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport AT dettorregabriella managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport AT capriasaveria managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport AT chiarettisabina managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport |